Trial Profile
A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac to the Subunit Influenza Vaccine Agrippal in Healthy Children, Adults and Elderly in China.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2013
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Solvay Pharmaceuticals
- 12 Nov 2006 New trial record.